Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21970099 | 0.86 | DPP4 (0.42) | DPP4GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL21903321 | 0.84 | DPP4 (0.40) | DPP4GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL21971002 | 0.79 | LMNA (0.46) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL13213025 | 0.78 | GABRG2 (0.47) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL21350132 | 0.78 | S100A4 (0.39) | DPP4GABRA1S100A4 | |
| SCHEMBL21970112 | 0.78 | GABRG2 (0.40) | DPP4GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL21903254 | 0.77 | PRF1 (0.38) | GABRA1 | |
| SCHEMBL21970103 | 0.77 | MAP3K5 (0.46) | GABRA1 | |
| SCHEMBL29985869 | 0.77 | MAP3K5 (0.46) | GABRA1 | |
| SCHEMBL29985638 | 0.77 | PRF1 (0.38) | GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140438-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140438-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM3, GRM1, GRM2 | DPP4 3299/4885GABRG2 37/4885GABRB3 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.